Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial evaluates the rate of onset of bronchodilator action of aclidinium bromide compared to placebo and tiotropium in patients with severe COPD after a single dose treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bromides; Tiotropium Bromide

Criteria

Inclusion Criteria:

• Males and females aged ≥ 40 years

• Current or ex-smokers of ≥ 10 pack-year

• Clinical diagnosis of severe stable COPD

Exclusion Criteria:

• History or current diagnosis of asthma, allergic rhinitis, or atopy

• Respiratory tract infection or acute COPD exacerbation in the last 6 weeks

• Hospitalised for an acute COPD exacerbation in the last 3 months

• Evidence of contraindicated use of anticholinergic drugs